Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:SLN
CUSIPN/A
Phone+44-20-34576900
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-34,475.00%
Return on Equity-21.42%
Return on Assets-20.54%
Miscellaneous
EmployeesN/A
Outstanding Shares69,990,000
Market Cap£136.14 million
Silence Therapeutics (LON:SLN) Frequently Asked Questions
What is Silence Therapeutics' stock symbol?
Silence Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SLN."
How were Silence Therapeutics' earnings last quarter?
Silence Therapeutics plc (LON:SLN) released its quarterly earnings data on Tuesday, September, 11th. The company reported ($12.40) earnings per share for the quarter. Silence Therapeutics had a negative return on equity of 21.42% and a negative net margin of 34,475.00%. View Silence Therapeutics' Earnings History.
What price target have analysts set for SLN?
1 equities research analysts have issued twelve-month price objectives for Silence Therapeutics' stock. Their forecasts range from GBX 277 to GBX 277. On average, they expect Silence Therapeutics' stock price to reach GBX 277 in the next year. This suggests a possible upside of 132.8% from the stock's current price. View Analyst Price Targets for Silence Therapeutics.
What is the consensus analysts' recommendation for Silence Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Silence Therapeutics.
Who are some of Silence Therapeutics' key competitors?
Some companies that are related to Silence Therapeutics include Starpharma (SPL), MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Protalix Biotherapeutics (PLX), Neptune Wellness Solutions (NEPT), Monash IVF Group (MVF), ABcann Global (ABCN), Horizon Discovery Group (HZD), IMV (IMV), Faron Pharmaceuticals Oy (FARN), Bionomics (BNO) and Fennec Pharmaceuticals (FRX).
Who are Silence Therapeutics' key executives?
Silence Therapeutics' management team includes the folowing people:
- Mr. David J. Ellam, CFO, Sec. & Director (Age 54)
- Dr. David Horn Solomon, CEO & Director (Age 58)
- Dr. Mark Cameron, Head of Chemistry
- Mr. Richard Jenkins, Head of Clinical Devel.
How do I buy shares of Silence Therapeutics?
Shares of SLN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Silence Therapeutics' stock price today?
One share of SLN stock can currently be purchased for approximately GBX 119.
How big of a company is Silence Therapeutics?
Silence Therapeutics has a market capitalization of £136.14 million.
What is Silence Therapeutics' official website?
How can I contact Silence Therapeutics?
Silence Therapeutics' mailing address is 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom. The company can be reached via phone at +44-20-34576900.
MarketBeat Community Rating for Silence Therapeutics (LON SLN)
MarketBeat's community ratings are surveys of what our community members think about Silence Therapeutics and other stocks. Vote "Outperform" if you believe SLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
